Ads3 completes strategic investment from Animoca Brands to reshape the Web3 advertising ecosystem
On December 19, Web3 intelligent advertising platform Ads3 announced the completion of a new round of strategic financing from Animoca Brands. This round of financing will strongly drive Ads3's global market expansion and empower the innovation and large-scale development of the decentralized advertising ecosystem. Previously, Ads3 had already received support from several well-known industry institutions such as Web3 Labs, AB Foundation, and Footprint Analytics. The completion of this round of financing further demonstrates the high recognition from leading capital for Ads3's vision of bridging the value systems of Web2 and Web3 and reconstructing advertising infrastructure. The intelligent advertising system integrates on-chain and off-chain data to automatically match user tags, enabling precise cross-ecosystem targeting. In terms of growth strategy, Ads3 has established exclusive partnerships with several mainstream mobile phone manufacturers, deeply integrating into native mobile device advertising networks, and directly reaching large-scale real users in key emerging markets such as Western Europe, Southeast Asia, and the Middle East. This infrastructure-level deployment allows Web2 users to seamlessly enter the Web3 ecosystem, and also helps advertisers maximize their ROI under the premise of compliance and efficiency through data-driven billing models such as OCPC and OCPM that are oriented toward performance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
